We were able to rank most of the psychotropics based on the available evidence and recommendations from subject matter experts .
There were few discrepancies between published evidence and the expert panel in ranking these drugs .
Conclusion Potential for weight gain is an important consideration in choice of any psychotropic .
This tool will help clinicians select psychotropics on a case-by-case basis in order to minimize the impact of weight gain when making both intra-class and interclass choices
Introduction Psychotropic medication use is associated with  weight gain .
While there are studies and review s comparing weight gain for psychotropics within some classes , clinicians frequently use drugs from different classes to treat psychiatric disorders .
Objective To undertake a systematic review of all classes of psychotropics to provide an all encompassing evidence -based tool that would allow clinicians to determine the risks of weight gain in making both intra-class and interclass choices of psychotropics .
Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
AIM Perospirone is classified as a second-generation antipsychotic agent for the treatment of schizophrenia .  Perospirone binds with high affinity to serotonin 5-HT2A receptors and dopamine D2 receptors . There are no reports of clinical comparisons of perospirone and risperidone in multicenter studies . To clarify the clinical traits of perospirone in the treatment of schizophrenia , the clinical efficacies and side-effects of perospirone and risperidone were compared in a r and omized clinical multicenter trial . METHODS Sixty-six schizophrenia patients were enrolled in the trial . The Positive and Negative Syndrome Scale ( PANSS ) total , positive , negative and general symptoms scores and Drug-Induced Extra-Pyramidal Symptoms Scale ( DIEPSS ) scores were investigated at 0 , 4 , 8 and 12 weeks . RESULTS Significant reductions in the PANSS total and subscale scores were observed in both the perospirone and risperidone groups , with no significant between-group differences at 4 and 12 weeks . Risperidone improved the total scores and overall psychopathologic symptom total scores more effectively than perospirone at week 8 . There were no significant differences in the DIEPSS scores at 0 , 4 , 8 and 12 weeks between the perospirone and risperidone groups . The numbers of patients who dropped out did not differ between the perospirone and risperidone groups . CONCLUSIONS Perospirone was as effective as risperidone against positive and negative symptoms in patients with schizophrenia . Both antipsychotic agents were equally well-tolerated
We were able to rank most of the psychotropics based on the available evidence and recommendations from subject matter experts .
There were few discrepancies between published evidence and the expert panel in ranking these drugs .
Conclusion Potential for weight gain is an important consideration in choice of any psychotropic .
This tool will help clinicians select psychotropics on a case-by-case basis in order to minimize the impact of weight gain when making both intra-class and interclass choices
Introduction Psychotropic medication use is associated with  weight gain .
While there are studies and review s comparing weight gain for psychotropics within some classes , clinicians frequently use drugs from different classes to treat psychiatric disorders .
Objective To undertake a systematic review of all classes of psychotropics to provide an all encompassing evidence -based tool that would allow clinicians to determine the risks of weight gain in making both intra-class and interclass choices of psychotropics .